Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK1119711A Pandemic Influenza Vaccine Schedules
NCT00430521Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2007
- Primary completion
- Oct 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) in Influenza A H5N1 infection (H5N1) (8 arms), sponsored by GSK. Primary endpoints: Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value, Geometric Mean Titers (GMTs) of H5N1 HI Antibodies and 9 more. Started Feb 2007; status: completed.
02
Drugs
prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT00430521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00430521.